z-logo
open-access-imgOpen Access
Enhanced Reprogramming Efficiency and Kinetics of Induced Pluripotent Stem Cells Derived from Human Duchenne Muscular Dystrophy
Author(s) -
Pooja Teotia,
Sujata Mohanty,
Madhulika Kabra,
Sheffali Gulati,
Balram Airan
Publication year - 2015
Publication title -
plos currents
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.282
H-Index - 49
ISSN - 2157-3999
DOI - 10.1371/currents.md.a77c2f0516a8cb4809ffad5963342905
Subject(s) - induced pluripotent stem cell , reprogramming , duchenne muscular dystrophy , muscular dystrophy , stem cell , basic fibroblast growth factor , microbiology and biotechnology , biology , medicine , bioinformatics , cell , genetics , embryonic stem cell , growth factor , gene , receptor
The generation of disease-specific induced pluripotent stem cells (iPSCs) holds a great promise for understanding disease mechanisms and for drug screening. Recently, patient-derived iPSCs, containing identical genetic anomalies of the patient, have offered a breakthrough approach to studying Duchenne muscular dystrophy (DMD), a fatal disease caused by the mutation in the dystrophin gene. However, development of scalable and high fidelity DMD-iPSCs is hampered by low reprogramming efficiency, the addition of expensive growth factors and slow kinetics of disease-specific fibroblasts. Here, we show an efficient generation of DMD-iPSCs on bFGF secreting human foreskin fibroblast feeders (I-HFF) by employing single polycistronic lentiviral vector for delivering of transcription factors to DMD patient-specific fibroblast cells. Using this method, DMD-iPSCs generated on I-HFF feeders displayed pluripotent characteristics and disease genotype with improved reprogramming efficiency and kinetics over to mouse feeders. Moreover, we were able to maintain disease-specific iPSCs without additional supplementation of bFGF on I-HFF feeders. Our findings offer improvements in the generation of DMD-iPSCs and will facilitate in understanding of pathological mechanisms and screening of safer drugs for clinical intervention.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here